Shopping Cart 0
Cart Subtotal
USD 0

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Pipeline Review, H2 2018

Summary

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Telomerase Reverse Transcriptase-Pipeline Review, H2 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 2, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Male Health, Respiratory, Hematological Disorders and Women's Health which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Gastric Cancer, Ovarian Cancer, Aplastic Anemia, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Lung Adenocarcinoma, Lymphoma, Male Infertility, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Pulmonary Fibrosis, Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Women Infertility.

Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)

- The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects

- The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Overview

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Companies Involved in Therapeutics Development

Asterias Biotherapeutics Inc

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd

GemVax & KAEL Co Ltd

Geron Corp

Inovio Pharmaceuticals Inc

Invectys SA

Komipharm International Co Ltd

Mediolanum farmaceutici SpA

Takis Srl

Telocyte LLC

TILT Biotherapeutics Ltd

Ultimovacs AS

Vaxon Biotech

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Drug Profiles

Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETS-2300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate TERT for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imetelstat sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-1400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INVAC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KML-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ribovax-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Telomerase for Men Infertility and Women Infertility-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TERT for Prostate Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Telomerase for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEL-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TILT-234-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCPVax-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UV-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-021-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Dormant Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Discontinued Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)-Product Development Milestones

Featured News & Press Releases

Sep 04, 2018: Asterias Biotherapeutics announces positive outcome from Second Safety Review Committee Meeting and open enrollment for VAC2 clinical trial in non-small cell lung cancer (NSCLC)

Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab

Jul 11, 2018: Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

Jun 28, 2018: Southampton vaccinate first patient to phase 1 study

Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

Jun 18, 2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress

Jun 12, 2018: Cancer Research Uk Tests First Of Its Kind Vaccine To Treat Lung Cancer

May 17, 2018: Geron Announces Oral Presentation at European Hematology Association Congress

May 16, 2018: Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress

Apr 25, 2018: Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2

Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia

Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models

Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres

Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2

Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Asterias Biotherapeutics Inc, H2 2018

Pipeline by e-Therapeutics Plc, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by GemVax & KAEL Co Ltd, H2 2018

Pipeline by Geron Corp, H2 2018

Pipeline by Inovio Pharmaceuticals Inc, H2 2018

Pipeline by Invectys SA, H2 2018

Pipeline by Komipharm International Co Ltd, H2 2018

Pipeline by Mediolanum farmaceutici SpA, H2 2018

Pipeline by Takis Srl, H2 2018

Pipeline by Telocyte LLC, H2 2018

Pipeline by TILT Biotherapeutics Ltd, H2 2018

Pipeline by Ultimovacs AS, H2 2018

Pipeline by Vaxon Biotech, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

Discontinued Products, H2 2018 (Contd..1), H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Therapeutic Products under Development, Key Players in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Therapeutics, Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Pipeline Overview, Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Pipeline, Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Pipeline Assessment


Companies

Asterias Biotherapeutics Inc

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd

GemVax & KAEL Co Ltd

Geron Corp

Inovio Pharmaceuticals Inc

Invectys SA

Komipharm International Co Ltd

Mediolanum farmaceutici SpA

Takis Srl

Telocyte LLC

TILT Biotherapeutics Ltd

Ultimovacs AS

Vaxon Biotech